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Abstract
Purpose To report the behavior of intravitreal Ozurdex
®
implant in eyes with post-lensectomy–vitrectomy (PLV)
aphakia.
Methods Retrospective chart review of three eyes with PLV
aphakia (three patients with uveitis) who received intra-
vitreal injection of Ozurdex
® for cystoid macular edema
(one eye), persistent inflammation (one eye), and ocular
hypotony (one eye). Final outcome was assessed in terms of
effectiveness, stability, and tolerance of the implant.
Results Following the implant, an initial improvement was
seen in all the three eyes. However, the implant migrated
into the anterior chamber (AC) at 1 week in two eyes and at
5 weeks in one eye, and wandered between the AC and
vitreous cavity with changing postures of the patient. Two
eyes developed corneal edema, of which one eye underwent
implant removal from the AC.
Conclusion Ozurdex
® implant should be contraindicated in
eyes with PLVaphakia to avoid its deleterious effect on the
corneal endothelium.
Keywords Aphakia.Intravitreal injection.Ozurdex
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Uveitis.Lensectomy.Vitrectomy
Corticosteroids have been the mainstay for treatment of
noninfectious uveitis. They can be administered systemically
or locally by topical, periocular, or intravitreal routes.
Persistent inflammation and cystoid macular edema (CME)
secondary to ocular inflammation are often vision-threatening
and pose a significant therapeutic challenge.
The Ozurdex
® (Ozurdex
®; Allergan, Inc, Irvine, CA,
USA) dexamethasone drug delivery system (DDS) is a
biodegradable intravitreal implant that delivers sustained
release of 700 μg of preservative-free dexamethasone to the
retina and vitreous. It is approved by the United States
Food and Drug Administration as a first-line therapy for the
treatment of macular edema following branch or central
retinal vein occlusion, as well as for noninfectious posterior
uveitis [1–3].
The results of its use in uveitis in clinical practice and
animal models for controlling inflammation and improving
CME and visual acuity have been encouraging [4, 5].
However, it has not been studied in aphakic eyes with
uveitis so far. We report our experience with the intravitreal
use of Ozurdex
® implant in three eyes (three patients) with
post-lensectomy–vitrectomy (PLV) aphakia.
Methods
We did a retrospective chart review of three patients with
uveitis who received intravitreal Ozurdex
® in eyes with
PLV aphakia. Demographic features, location and etiology
of uveitis, systemic therapy and surgical intervention prior
to Ozurdex
® injection, indications for the injection, best
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(IOP) before and after injection, and final outcome in
terms of effect, stability, and tolerance of the implant were
noted. Ozurdex
® was injected into the vitreous cavity under
sterile conditions in accordance with the manufacturer’s
instructions.
Results
All three patients were males (Tables 1 and 2). All three
aphakic eyes had undergone pars plana lensectomy (PPL)
and pars plana vitrectomy (PPV) for visually disabling
cataract due to chronic uveitis. The indications for Ozurdex
®
injection were CME (one eye), persistent intraocular inflam-
mation (one eye), and ocular hypotony (one eye). An initial
improvement was seen in all the three eyes post-injection.
However, the implant migrated into the anterior chamber
(AC) at 1 week (two eyes) and 5 weeks (one eye) post-
injection and wandered between the AC and vitreous cavity
with changing postures of the patient. Further follow-up
revealed its adverse effect on the corneal endothelium in
two eyes till the last visit, compromising visual acuity and
IOP.
Case reports
Case 1 A 47-year-old male was referred to our clinic with
bilateralchronicanterior uveitis of 5years duration.TheBCVA
was counting fingers in both eyes and IOP 15 mmHg and
10 mmHg in the right and left eye, respectively. The anterior
segment showed 1+ cells and 1+ flare, with multiple posterior
synechiae and significant cataract in both eyes. The posterior
segment was unremarkable. Topical anti-inflammatory and
cycloplegic therapy was started, along with oral corticosteroids
and immunosuppressive therapy (azathioprine, 2 mg/kg/day).
At 8 months of follow-up in our clinic, he underwent PPL and
PPVin the left eye. At 8 weeks postoperatively, the left eye had
BCVA 6/24, IOP 15 mmHg and significant CME (Fig. 1a).
Despite systemic and local therapy, the CME persisted in this
eye at 4 months with BCVA 6/24 and IOP 15 mmHg. He was
given Ozurdex
® injection. At 1 week post-injection, the CME
resolved although the BCVA remained 6/24. The IOP was
11 mmHg. However, the Ozurdex
® implant migrated into the
AC, and there were descemet’s folds with corneal edema
(Fig. 1b). At 18 days post-injection, the BCVA was 6/24, IOP
16 mmHg; cornea was clear; there was no CME, and the
implant was back in the vitreous cavity. The patient was
cautioned and instructed to avoid prone position. On his last
Table 1 Baseline characteristics and behavior of intravitreal Ozurdex implant in post-lensectomy–vitrectomy aphakic eyes
Case Age Sex Diagnosis Eye Pre-implant
BCVA
Pre-implant
IOP (mmHg)
Indication
for Ozurdex
implant
Treatment Interval between
implantation and
migration into AC
1 47 M Chronic anterior
uveitis
Right 6/24 15 Cystoid macular
edema
Oral CS+azathioprine 1 week
2 13 M Behcets
disease
Right Counting
fingers
14 Persistent
intraocular
inflammation
Oral CS+azathioprine/
infliximab/cyclosporine
8 days
3 15 M Chronic anterior
uveitis
Right 6/36 6 Ocular hypotony Topical anti-inflammatory/
cycloplegic therapy
5 weeks
M male, BCVA best corrected visual acuity, IOP intraocular pressure, CS corticosteroids, AC anterior chamber
Table 2 Outcome of intravitreal Ozurdex implant in post-lensectomy–vitrectomy aphakic eyes
Adverse effects
of migrated implant
Surgical removal
of Ozurdex implant
Final outcome Post-implant
BCVA
Post-implant
IOP (mmHg)
Follow-up
after implant
migration, months
Final location
of the implant
Corneal edema No Resolution of cystoid
macular edema;
resolution of
corneal edema
6/18 12 4 Vitreous cavity
Corneal edema,
elevation of IOP
Yes, 40 days after
implantation
Regression of
inflammation, control
of IOP, corneal
edema persisted
6/18 33 4 Removed from
the eye
None No Improvement of hypotony 6/6 12 3 Vitreous cavity
2 J Ophthal Inflamm Infect (2012) 2:1–5visit, at 4 months post-injection, the BCVA was 6/24, IOP
12 mmHg, cornea was clear, and the implant was in the
vitreous cavity (Fig. 1c). The OCT showed few intraretinal
cystic spaces (Fig. 1d).
Case 2 A 13-year-old male with Behcets disease presented
to our center with bilateral panuveitis involving vasculitis
and retinitis, treated elsewhere for 4 years. Despite sequential
immunosuppressive therapy with azathioprine, infliximab,
and cyclosporine, he had persistent vasculitis and retinitis in
both eyes. The BCVAwas counting fingers in both eyes with
significant cataract. The IOP was 14 mmHg and 16 mmHg in
the right and left eye, respectively. At 17 months of follow-up
in our clinic, he underwent PPL and PPV in the right eye for
complicated cataract. At 4 weeks postoperative, the BCVA
improved to 6/18. However, new retinitis lesions appeared in
the right eye. The IOP was 10 mmHg. He was given
intravitreal Ozurdex
®. Eight days post-injection, the BCVA
was 6/18 and IOP 18 mmHg. The retinitis lesions regressed
significantly. However, the Ozurdex
® implant had migrated
into the AC. Cornea was clear. On the 14
th post-injection
day, the BCVA was 6/18 and IOP was 18 mmHg. The
implant was in the AC, and there was significant corneal
edema in the lower half (Fig. 2a). Repositioning of the
patient was attempted several times, but the implant would
come back into the AC frequently. The IOP recorded on 18
th
post-injection day was 28 mmHg. Topical dorzolamide
hydrochloride 2% and timolol maleate 0.5% eyedrops were
started. Despite combination anti-glaucoma therapy for
Fig. 1 a Optical coherence tomography (OCT) of the left eye of a 47-
year-old male (case 1) showing cystoid macular edema (CME)
8 weeks following pars plana lensectomy and vitrectomy for
significant cataract due to chronic anterior uveitis. b Slit lamp
photograph of anterior segment of the same eye as in (a), 1 week
after the intravitreal implantation of Ozurdex
®, showing migration of
the implant into the anterior chamber with corneal edema. c Slit lamp
photograph of the same eye as in (a, b), showing clear cornea
4 months after Ozurdex migration. d Optical coherence tomography
(OCT) of the same eye as in a–c, showing insignificant intraretinal
cystic spaces 3 months after intravitreal implantation of Ozurdex
®
Fig. 3 Slit lamp photograph of anterior segment of the right eye,
following pars plana lensectomy and vitrectomy with SF6 tamponade
with intravitreal injection of Ozurdex
® for complicated cataract, in a
15-year-old male (case 3) showing migration of implant into the AC,
5 weeks after the surgery
Fig. 2 a Slit lamp photograph
of the anterior segment of the
right eye (following pars plana
lensectomy and vitrectomy for
complicated cataract) in a 13-
year-old male with Behcets dis-
ease(case 2) showing migration
of the Ozurdex
® implant into the
anterior chamber and corneal
edema, 14 days after intravitreal
injection of Ozurdex
®. b Same
eye as in (a), 3 months after the
removal of Ozurdex
® implant,
showing persistent corneal ede-
ma, despite surgical removal of
the implant
J Ophthal Inflamm Infect (2012) 2:1–5 317 days, the IOP rose to 33 mmHg on 35
th post-injection
day. Because of persistent corneal edema and raised IOP, the
implant was surgically removed from the AC. Three months
following its removal, the BCVA was 6/24 and IOP was
17 mmHg. Diffuse corneal edema decreased (Fig. 2b)b u t
persisted, and the posterior segment was quiescent.
Case 3 A 15-year-old male with idiopathic chronic anterior
uveitis in the right eye since 4 years had BCVA 6/36 and IOP
6 mmHg. The lefteye was normal. He had significant cataract
inthe right eye and underwent PPL and PPV. Intraoperatively,
atrophy of ciliary processes was noted along with multiple
peripheralretinalbreaks.AninternaltamponadewithSF6 was
done along with intravitreal injection of Ozurdex
®.A t
3 weeks postoperative, the BCVA was 6/12 and IOP was
18 mmHg. The eye was quiet, and the Ozurdex
® implant was
well placed in the vitreous cavity inferiorly. At 5 weeks, the
implant was found lying inferiorly in the AC (Fig. 3). The
BCVA was 6/12, and IOP was 8 mmHg. The cornea was
clear. The implant migrated back into the vitreous cavity
once the patient attained supine position. On his last visit at
4 months, the BCVA was 6/6, IOP 12 mmHg, and the eye
was quiescent with the implant in the vitreous cavity.
Discussion
Ozurdex
® has been reported to be well tolerated in uveitis as
well as in retinal disorders. So far, the ocular adverse effects
reported after intravitreal injection include cataract formation,
IOP elevation, subconjunctival hemorrhage, hyperemia, and
conjunctival edema. These are often temporary and can be
medically managed.
In all our patients described above, there was an initial
improvement following intravitreal Ozurdex
® injection, in
terms of CME (one eye), control of inflammation (one eye),
and hypotony (one eye). However, the retention of Ozurdex
®
implant in the vitreous cavity became a major challenge as it
wandered between the AC and the vitreous cavity.
The IOP elevation was temporary and was medically
managed. Corneal edema could be medically managed in
one eye but necessitated a repeat surgical intervention in the
other eye for removal of the Ozurdex
® implant.
The encouraging role of Ozurdex
® is due to its potency,
dose consistency, extended duration of action, and minimal
adverse effects [4–8]. Additional advantages of the biode-
gradable DDS are that they do not need to be retrieved and
can be administered repeatedly. Myung et al. reported
successful control of inflammation and CME in their patients
with uveitis [4]. No serious ocular or systemic adverse
effects were noted during the mean follow-up (post-
injection) time of 5.25 months. The only concern in their
experience with the implant was a shorter durability of its
effect (about 3 to 4 months) than the typical 6-month period
reported in retinal vein occlusion [1].
While the efficacy of Ozurdex
® in uveitis has been
proved in clinical trials [2, 3], clinical case series [4], and
experimental animal studies [5], none of the studies have
reported its use and outcome in aphakic eyes of patients
with uveitis after PPL and PPV.
The use of Ozurdex
® implant in vitrectomized eyes with
diabetic macular edema has been reported recently by Boyer
et al [9]. Their patients were phakic/pseudophakic, and the
implant was well tolerated with an acceptable safety profile.
Moreover, the authors believed that vitrectomized eyes
responded well to sustained drug delivery with an implant.
To the best of our knowledge, our series is the first to
report the behavior of Ozurdex
® implant and its outcome in
eyes with PLV aphakia. In aphakic–vitrectomized eyes, the
implant is placed within the vitreous cavity actually filled
with aqueous fluid and therefore has the potential to
migrate back and forth with changing postures and minimal
resistance leading to complications as seen in our patients.
Such behavior of the implant in these eyes is not
unexpected. Moreover, the anterior migration of the implant
at 5 weeks in case 3 after absorption of the gas may reflect
the buoyancy of the implant in aqueous fluid and tendency
to shift. We believe that Ozurdex
® injection should be
contraindicated in eyes with PLV aphakia, even in the
presence of recalcitrant macular edema due to any cause, to
avoid its deleterious effect on the corneal endothelium.
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